arsenic has been researched along with everolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhuta, S; Ding, B; Huang, J; Liu, N; Sun, Y; Tai, S; Thor, RK | 1 |
| Liang, C; Tai, S; Xu, L; Xu, M; Zhang, K; Zhang, L; Zhang, Y | 1 |
2 other study(ies) available for arsenic and everolimus
| Article | Year |
|---|---|
Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Caspase 3; Caspase 7; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Mice; Mice, SCID; Ovarian Neoplasms; Oxides; Phosphoproteins; Proto-Oncogene Proteins c-akt; Sirolimus; Xenograft Model Antitumor Assays | 2012 |
Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Cell Line, Tumor; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Male; Mice, SCID; Microscopy, Fluorescence; Microtubule-Associated Proteins; Oxides; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2017 |